Treatment of HIV infection with raltegravir

被引：0
|
作者：
Chirch, Lisa M. [1 ]
Morrison, Sidonie A. [1 ]
Steigbigel, Roy T. [1 ]
机构：
[1] SUNY Stony Brook, Sch Med, Div Infect Dis, Stony Brook, NY 11794 USA
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2009年 / 10卷 / 07期
关键词：
antiretroviral therapy; HIV; human immunodeficiency virus; integrase inhibitor; raltegravir; INTEGRASE INHIBITOR RALTEGRAVIR; STRAND TRANSFER; PHARMACOKINETICS; TOLERABILITY; MK-0518; THERAPY; SAFETY; VIRUS;
D O I：
10.1517/14656560902911488
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Background: Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is now available for the treatment of drug-resistant virus. Objective: To establish raltegravir as an effective addition to the existing antiretroviral armamentarium by reviewing pharmacokinetics, efficacy, safety and tolerability. Methods: Data from pharmacokinetic, Phase II and III clinical trials were reviewed. Results/conclusions: Results from clinical trials indicate that raltegravir is safe and highly effective in the treatment of both antiretroviral-naive and -experienced patients.
引用
收藏
页码：1203 / 1211
页数：9
相关论文
共 50 条
  • [21] HIV resistance to raltegravir
    Clavel F.
    European Journal of Medical Research, 14 (Suppl 3) : 47 - 54
  • [22] Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection
    Cooper, David A.
    Steigbigel, Roy T.
    Gatell, Jose M.
    Rockstroh, Jurgen K.
    Katlama, Christine
    Yeni, Patrick
    Lazzarin, Adriano
    Clotet, Bonaventura
    Kumar, Princy N.
    Eron, Joseph E.
    Schechter, Mauro
    Markowitz, Martin
    Loutfy, Mona R.
    Lennox, Jeffrey L.
    Zhao, Jing
    Chen, Joshua
    Ryan, Desmond M.
    Rhodes, Rand R.
    Killar, John A.
    Gilde, Lucinda R.
    Strohmaier, Kim M.
    Meibohm, Anne R.
    Miller, Michael D.
    Hazuda, Daria J.
    Nessly, Michael L.
    DiNubile, Mark J.
    Isaacs, Robin D.
    Teppler, Hedy
    Nguyen, Bach-Yen
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (04): : 355 - 365
  • [23] Long-term efficacy and safety of raltegravir in the management of HIV infection
    Liedtke, Michelle D.
    Tomlin, C. Ryan
    Lockhart, Staci M.
    Miller, Misty M.
    Rathbun, R. Chris
    INFECTION AND DRUG RESISTANCE, 2014, 7 : 73 - 84
  • [24] Elevated alkaline phosphatase with raltegravir in a treatment experienced HIV patient
    Fleischbein, Eric
    O'Brien, John
    Martelino, Ryan
    Fenstersheib, Martin
    AIDS, 2008, 22 (17) : 2404 - 2405
  • [25] Raltegravir: the first in a new class of integrase inhibitors for the treatment of HIV
    Sayana, Shilpa
    Khanlou, Homayoon
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2008, 6 (04) : 419 - 426
  • [26] Raltegravir Once-Daily Tablet: A Review in HIV-1 Infection
    Emma D. Deeks
    Drugs, 2017, 77 : 1789 - 1795
  • [27] Pharmacokinetics of double-dose raltegravir in two patients with HIV infection and tuberculosis
    Burger, David M.
    Magis-Escurra, Cecile
    van den Berk, Guido E. L.
    Gelinck, Luc B. S.
    AIDS, 2010, 24 (02) : 328 - 330
  • [28] Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc
    Armstrong-James, Darius
    Stebbing, Justin
    Scourfield, Andrew
    Smit, Erasmus
    Ferns, Bridget
    Pillay, Deenan
    Nelson, Mark
    ANTIVIRAL RESEARCH, 2010, 86 (02) : 224 - 226
  • [29] Effect of HIV infection and menopause status on raltegravir pharmacokinetics in the blood and genital tract
    Cottrell, Mackenzie L.
    Patterson, Kristine B.
    Prince, Heather M. A.
    Jones, Amanda
    White, Nicole
    Wang, Ruili
    Kashuba, Angela D. M.
    ANTIVIRAL THERAPY, 2015, 20 (08) : 795 - 803
  • [30] Raltegravir Once-Daily Tablet: A Review in HIV-1 Infection
    Deeks, Emma D.
    DRUGS, 2017, 77 (16) : 1789 - 1795
12345